Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AIM ImmunoTechAIM -14.97%22 3-Year EBITDA Growth Rate is 42.00% as of Jun. 2026, which is 27% above its 10-year median of 33.20. GuruFocus rates AIM with a GF Score™ of 22/100 and a GF Value™ of $0.92 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,130 Biotechnology companies, AIM ImmunoTech ranks better than 79.82% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 42.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 21.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 43.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of AIM ImmunoTech was 65.80% per year. The lowest was -21.20% per year. And the median was 33.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
AIM ImmunoTech 3-Year EBITDA Growth Rate Related Terms
AIM vs NIKI, PMCB, PCSA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, AIM ImmunoTech's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AIM ImmunoTech 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where AIM ImmunoTech's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 42.00% mean?
AIM ImmunoTech (AIM) has a 3-Year EBITDA Growth Rate of 42.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for AIM ImmunoTech and its competitors. This is 27% above median its historical median of 33.20. According to the industry distribution chart, AIM ImmunoTech ranks #228 out of 1130 companies in the Biotechnology industry, placing it in the top 20.2%.
Is AIM ImmunoTech's 3-Year EBITDA Growth Rate too high?
AIM ImmunoTech's current 3-Year EBITDA Growth Rate of 42.00% is 27% above median its 10-year median of 33.20. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. AIM ImmunoTech's value of 42.00% is 182.8% above this industry median. Based on the distribution chart, AIM ImmunoTech ranks #228 out of 1130 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AIM ImmunoTech has a GF Score™ of 22/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's 3-Year EBITDA Growth Rate compare to NIKI and PMCB?
According to the Biotechnology industry distribution chart, AIM ImmunoTech ranks #228 out of 1130 companies for 3-Year EBITDA Growth Rate. This places AIM ImmunoTech in the top 20% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.85. AIM ImmunoTech's value of 42.00% is 182.8% above this benchmark. While the company's 10-year median is 33.20 vs. the industry median of 14.85, AIM ImmunoTech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AIM ImmunoTech's current 3-Year EBITDA Growth Rate of 42.00% is 182.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for AIM ImmunoTech and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AIM ImmunoTech's current 3-Year EBITDA Growth Rate is 42.00%, which is 27% above median its own 10-year median of 33.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
Based on GuruFocus' analysis, AIM ImmunoTech (AIM) is currently considered Possible Value Trap. The stock's GF Value™ is $0.92, compared to a current price of $0.22 — trading 76.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 42.00%, which is 27% above median its 10-year median of 33.20 and 182.8% above the Biotechnology industry median of 14.85. AIM ImmunoTech's overall GF Score™ is 22/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For AIM ImmunoTech (AIM), the current 3-Year EBITDA Growth Rate is 42.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AIM ImmunoTech (AIM) Overvalued in 2026?
Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued.
The current stock price of $0.22 is trading 76.1% below its estimated GF Value™ of $0.92.
GuruFocus considers AIM ImmunoTech to be Possible Value Trap.
Key valuation signals for AIM:
3-Year EBITDA Growth Rate: 42.00% (27% above median its 10-year median of 33.20)
GF Value™: $0.92 vs. price of $0.22 (76.1% below fair value)
Industry Position: 182.8% above the Biotechnology median (#228 of 1130)
No single metric tells the full story. See the AIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
22GF Score
Get the complete analysis for AIM
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIM has been successfully added to your 
